Date: 2017-06-06
Type of information: Development agreement
Compound: CTX101 , allogeneic CAR-T therapies
Company: Crispr Therapeutics (Switzerland - UK) MaSTherCell (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: development - manufacturing - bioproduction
Action mechanism: cell therapy/gene therapy/CAR-T cell therapy. CTX101 is an allogeneic CAR T-cell therapy currently in development by CRISPR Therapeutics for the treatment of CD19 positive malignancies.
Disease: CD19 positive malignancies
Details:
- • On June 6, 2017, CRISPR Therapeutics and MaSTherCell announced the signing of an agreement to develop and manufacture allogeneic CAR-T therapies. MaSTherCell will be responsible for the development and cGMP manufacturing of CTX101 for use in clinical studies.
- The program utilizes CRISPR’s proprietary gene-editing technology to make targeted modifications to the T-cell, thereby enabling an allogeneic, or off-the-shelf, product that is applicable to a broader patient population and addresses the challenges of the current generation of autologous therapies.
Financial terms:
Latest news:
Is general: Yes
